Eurofins Launches Reagents for Automated Extraction of Genomic SARS-CoV-2 RNA from Clinical Swab Samples

Eurofins Technologies (Luxembourg) has launched reagents for automated isolation of high-quality SARS-CoV-2 RNA (ribonucleic acid) from viral particles of human respiratory specimens.

As COVID-19 continues to accelerate worldwide, diagnostic laboratories face an unprecedented demand for testing capacity. Eurofins' launch of the GSD NovaPrime RNA Extraction kits aims to help laboratories to meet this demand with an easy and highly efficient extraction method that works with a large range of existing automation equipment.

The GSD NovaPrime RNA Extraction AE1 kit is intended for the automated extraction of genomic SARS-CoV-2 RNA from human respiratory (nasal wash/swab, nasopharyngeal wash/swab, oropharyngeal swab) specimen types, specifically validated for the use with the KingFisher Flex System automation platform. The GSD NovaPrime RNA Extraction AE2 kit is intended for automated extraction of genomic SARS-CoV-2 RNA from human respiratory (nasal wash/swab, nasopharyngeal wash/swab, oropharyngeal swab) specimen types, specifically validated for the use with the MGI MGISP-960 automation platform.

The reagents’ magnetic bead-based, automated method extracts and isolates virus particles and their respective RNA on many open platforms for subsequent real-time RT-PCR (reverse transcription polymerase chain reaction) analysis using approved IVD kits. Both the kits are ideal for use with the GSD NovaPrime SARS-CoV-2 (COVID-19) RT-PCR clinical IVD assay for virus detection. The kits have to be validated as required by local legislation for their intended use by authorized clinical testing laboratories. Eurofins also plans to release a CE-IVD marked version of the kit at a later stage.

Related Links

Eurofins Technologies